RxDoctor Payments Data

Michael Bader, MD

Internal Medicine · Stoneham, MANPI 1184689804

Payments from drug & device makers

$8,077in general payments, 2019–2025

Across 55 payments — averaging $146.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • GSK$359
  • Teva Pharmaceuticals USA, Inc.$67
  • Pfizer$12

What the payments were for

  • Speaking & faculty fees$6,85085%
  • Travel & lodging$571%
  • Food & beverage$1,15214%
  • Education$180%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca28$7,639
GSK24$359
Teva Pharmaceuticals USA, Inc.2$67
Pfizer1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,077 in reported general payments places this provider in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$30,726
Medicare patients
190
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$31,591
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$29,923
EliquisApixaban40$25,429
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr17$18,302
Breo ElliptaFluticasone/Vilanterol32$17,338
Atorvastatin Calcium253$3,847
Albuterol Sulfate HfaAlbuterol Sulfate82$3,338
Metoprolol Succinate128$3,311
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,513
Pravastatin Sodium60$1,442
Rosuvastatin Calcium37$1,279
Levothyroxine Sodium100$1,033
SynthroidLevothyroxine Sodium28$988
Omeprazole60$875
Amlodipine Besylate116$793

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$359$67,23078 claims
AstraZenecaBreztri Aerosphere$7,639$29,92331 claims
PfizerEliquis$12$25,42940 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Stoneham

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →